[go: up one dir, main page]

WO2011063776A3 - Complexes solubles bêta-glucane-api pour utilisation pharmaceutique - Google Patents

Complexes solubles bêta-glucane-api pour utilisation pharmaceutique Download PDF

Info

Publication number
WO2011063776A3
WO2011063776A3 PCT/CZ2010/000122 CZ2010000122W WO2011063776A3 WO 2011063776 A3 WO2011063776 A3 WO 2011063776A3 CZ 2010000122 W CZ2010000122 W CZ 2010000122W WO 2011063776 A3 WO2011063776 A3 WO 2011063776A3
Authority
WO
WIPO (PCT)
Prior art keywords
water
soluble
glucan
complexes
apis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2010/000122
Other languages
English (en)
Other versions
WO2011063776A2 (fr
Inventor
Vladimir Kral
Jarmila Kralova
Kamil Zaruba
Miroslav Flieger
Zdenek Kejik
Pavel Martasek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2011063776A2 publication Critical patent/WO2011063776A2/fr
Anticipated expiration legal-status Critical
Publication of WO2011063776A3 publication Critical patent/WO2011063776A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des nouveaux complexes hydrosolubles bêta-glucane avec des ingrédiants pharmaceutiquement actifs (API) et leurs compositions pharmaceutiques. La formation de complexes hydrosolubles selon l'invention est réalisée par addition d'une solution d'API dans un solvant organique (de préférence, 2-propanol, tétrahydrofurane, dioxane) à la solution de glucane hydrosoluble en régulant le rapport eau/solvant organique. Pour les API hydrosolubles, tels que le doxorubicine, le complexe est formé par addition de la solution d'API à une solution de glucane aqueuse, puis par addition d'un solvant organique miscible dans l'eau entraînant une modification de la conformation du glucane et, par conséquent, la formation du complexe. La présente invention concerne des nouveaux complexes hydrosolubles d'API hydrosolubles et des nouvelles formes à libération lente d'API hydrosolubles. La préparation selon l'invention peut être appliquée pour une large gamme de stratégies de formulation, y compris les médicaments administrés par voie orale.
PCT/CZ2010/000122 2009-11-25 2010-11-25 Complexes solubles bêta-glucane-api pour utilisation pharmaceutique Ceased WO2011063776A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090790A CZ302789B6 (cs) 2009-11-25 2009-11-25 Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CZPV2009-790 2009-11-25

Publications (2)

Publication Number Publication Date
WO2011063776A2 WO2011063776A2 (fr) 2011-06-03
WO2011063776A3 true WO2011063776A3 (fr) 2012-05-31

Family

ID=43743524

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000120 Ceased WO2011063774A2 (fr) 2009-11-25 2010-11-25 Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes
PCT/CZ2010/000121 Ceased WO2011063775A2 (fr) 2009-11-25 2010-11-25 Complexes de sartans à base de pectine et compositions pharmaceutiques fabriquées à partir de ces complexes
PCT/CZ2010/000122 Ceased WO2011063776A2 (fr) 2009-11-25 2010-11-25 Complexes solubles bêta-glucane-api pour utilisation pharmaceutique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000120 Ceased WO2011063774A2 (fr) 2009-11-25 2010-11-25 Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes
PCT/CZ2010/000121 Ceased WO2011063775A2 (fr) 2009-11-25 2010-11-25 Complexes de sartans à base de pectine et compositions pharmaceutiques fabriquées à partir de ces complexes

Country Status (2)

Country Link
CZ (1) CZ302789B6 (fr)
WO (3) WO2011063774A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176531A2 (fr) * 2013-04-27 2014-10-30 The Regents Of The University Of California Utilisation d'un co-solvant pour produire des intermédiaires réactifs à partir de biomasse
CN103622928A (zh) * 2013-11-27 2014-03-12 广西大学 一种果胶基载体材料的制备方法及其应用
WO2019046582A1 (fr) 2017-08-30 2019-03-07 Antares Pharma, Inc. Formulations de triglycérides d'ester de testostérone
CN115252587A (zh) * 2022-08-19 2022-11-01 南京泛太化工医药研究所 一种口腔速溶膜及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392487A2 (fr) * 1989-04-13 1990-10-17 Takeda Chemical Industries, Ltd. Composition stabilisée contenant des anthracyclines
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
WO2006015627A1 (fr) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN EN TANT QUE VEHICULE POUR DES SUBSTANCES CHIMIQUES
US20070213393A1 (en) * 2001-05-01 2007-09-13 Angiotech International Ag Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
RO107187B1 (ro) 1992-02-11 1993-10-29 Icn Galenika Sa Compoziție farmaceutica, antiacida, stabilizata și procedeu de obținere
HU213872B (en) * 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
KR0121127B1 (ko) 1994-05-09 1997-11-13 강박광 이온성 고분자 네트웍을 갖는 피부약물전달체계
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
DK0876142T3 (da) * 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
IT1282381B1 (it) 1996-04-29 1998-03-20 Trans Bussan S A Nuove formulazioni di diacereina, ottenute per inclusione del principio attivo in idrogel polisaccaridi
IL127189A0 (en) 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
US5891441A (en) 1996-07-08 1999-04-06 Diaz; Jose A. Chemical composition and method for more rapidly aiding the absorption, binding an elimination of undigested fat in the human body
US6200574B1 (en) 1996-07-08 2001-03-13 Jose A. Diaz Chemical composition for aiding the absorption, binding and elimination of undigested fat
FR2752843B1 (fr) * 1996-08-30 1998-10-16 Sod Conseils Rech Applic Copolymeres reticules a base de polymeres polycarboxyliques et leur utilisation comme support de composition pharmaceutique
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040136961A1 (en) 1997-10-09 2004-07-15 Ales Prokop Nanoparticulate composition for efficient gene transfer
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
AU751182B2 (en) 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
RU2169002C2 (ru) 1999-04-19 2001-06-20 Пятигорская государственная фармацевтическая академия Способ получения инулин-пектинового концентрата в порошке для медицинских и пищевых целей из высушенного сырья
AU2002243267A1 (en) 2000-10-27 2002-06-24 Mannatech, Inc. Dietary supplement compositions
WO2003004033A1 (fr) 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Formulations d'oxymorphone a liberation lente
JP4339685B2 (ja) 2001-09-03 2009-10-07 ディーエスエム アイピー アセッツ ビー．ブイ． ペクチン及びアスコルビン酸を含む組成物
JP2003127783A (ja) 2001-10-25 2003-05-08 Mitsuboshi Belting Ltd フロアコンソール
DE10212553A1 (de) 2002-03-16 2003-09-25 Knoell Hans Forschung Ev Verwendung einer Formulierung zur in situ Biodegradation von Wundabdeckungen
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
DE10214005A1 (de) 2002-03-27 2003-10-09 Volker Bartz Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
DE20205184U1 (de) 2002-03-27 2002-12-19 Bartz, Volker, 35440 Linden Blutfettsenker zur oralen Einnahme
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
JP2004059440A (ja) 2002-07-25 2004-02-26 Mikasa Seiyaku Co Ltd 肌荒れ防止および粘膜修復剤
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
JP2004107295A (ja) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
CZ296475B6 (cs) 2002-12-09 2006-03-15 Mikrobiologický Ústav Av Cr Zpusob fermentacní prípravy extracelulárního glukanu pomocí hub Claviceps sp.
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040241223A1 (en) 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
CN100477999C (zh) 2003-12-29 2009-04-15 湖南华纳大药厂有限公司 胶体果胶铋分散片
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2005084648A1 (fr) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques comprenant du candesartan cilexetil
JPWO2005084703A1 (ja) 2004-03-09 2007-11-29 株式会社Ｎｒｌファーマ 徐放性の口腔用組成物
DE102004019916A1 (de) 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2005105040A2 (fr) 2004-04-26 2005-11-10 Micelle Products, Inc. Preparation hydrosoluble de vitamines liposolubles, agents pharmaceutiques et leurs applications
JP2008503583A (ja) 2004-06-22 2008-02-07 プロ−ファーマシューティカルズ，インコーポレイティド 抗がん薬、抗血管形成薬、及び多糖類を共デリバリーするための組成物及び方法
CN101039699B (zh) * 2004-10-15 2011-07-27 柳署弘 用于减小药物化合物毒性的方法和组合物
CA2595526A1 (fr) * 2005-02-09 2006-08-17 Da Volterra Administration au niveau du colon d'agents actifs
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2006122835A1 (fr) 2005-05-18 2006-11-23 Da Volterra Administration colonique d'adsorbants
CN100340295C (zh) 2005-06-29 2007-10-03 山西安特生物制药股份有限公司 一种口服复方胶体果胶铋制剂及制备方法
ES2279695B1 (es) 2005-08-01 2008-08-01 Jesus Antas Pharma, S.A. Nuevas formulaciones solidas de carotenoides y procedimiento para su obtencion.
JP4817042B2 (ja) 2005-08-26 2011-11-16 国立大学法人三重大学 Ａｌを含むＩＩＩ族窒化物結晶の作製方法、およびＡｌを含むＩＩＩ族窒化物結晶
US20070167395A1 (en) 2006-01-17 2007-07-19 Isaac Eliaz Compositions and methods for treating diabetes
KR101234799B1 (ko) * 2006-02-07 2013-02-20 삼성전자주식회사 이동 로봇 제어 장치 및 방법
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
CN101045163B (zh) 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 一种高分子抗癌前药及其制备方法和用途
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
CN100394923C (zh) 2006-05-26 2008-06-18 范晓青 低分子柑桔果胶用于调节血糖血脂和改善脂肪肝中的应用
US20070292480A1 (en) 2006-06-14 2007-12-20 Conopco, Inc., D/B/A Unilever Delivery System for Ingestible Components
CN101528224A (zh) * 2006-09-05 2009-09-09 阿斯利康(瑞典)有限公司 包含坎地沙坦西酯的药用组合物
EP2081557A1 (fr) 2006-11-17 2009-07-29 DA Volterra Distribution colique à l'aide de billes zn/pectine avec un revêtement d'eudragit
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
EP2172193A1 (fr) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Compositions de nanoparticules améliorées de composés faiblement solubles
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392487A2 (fr) * 1989-04-13 1990-10-17 Takeda Chemical Industries, Ltd. Composition stabilisée contenant des anthracyclines
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US20070213393A1 (en) * 2001-05-01 2007-09-13 Angiotech International Ag Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
WO2006015627A1 (fr) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN EN TANT QUE VEHICULE POUR DES SUBSTANCES CHIMIQUES

Also Published As

Publication number Publication date
WO2011063776A2 (fr) 2011-06-03
WO2011063774A3 (fr) 2012-01-19
CZ302789B6 (cs) 2011-11-09
WO2011063775A3 (fr) 2012-01-26
CZ2009790A3 (cs) 2011-06-01
WO2011063774A2 (fr) 2011-06-03
WO2011063775A2 (fr) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2008005819A3 (fr) Formulation ophtalmique contenant une sulfoalkyl éther cyclodextrine et corticostéroïde
WO2009019571A3 (fr) Procede de solubilisation d'huiles essentielles dans l'eau
WO2009066457A1 (fr) Composition de préparation externe comprenant du liquide ionique à base d'acides gras en tant qu'ingrédient actif
IN2011KN04251A (fr)
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
WO2011113855A3 (fr) Composition pharmaceutique pour le traitement d'une pression intraoculaire accrue
WO2012064126A3 (fr) Composition d'adhésif médical
WO2010119369A3 (fr) Crème médicale à base de sulfadiazine d'argent et de chitosane et son procédé de préparation
WO2007121352A3 (fr) Triterpénoïdes thérapeutiques
WO2011063776A3 (fr) Complexes solubles bêta-glucane-api pour utilisation pharmaceutique
WO2010045281A3 (fr) Formulations aqueuses stables de medicaments insolubles ou peu solubles dans l'eau
TW201129385A (en) Film-coating agent for solid formulation and solid formulation using the same
WO2009094457A3 (fr) Benzhydryléthers substitués
WO2006044771A3 (fr) Methodes et compositions pour reduire la toxicite d'un compose pharmaceutique
WO2008042841A3 (fr) Compositions du docétaxel
WO2010080754A3 (fr) Préparations pharmaceutiques nanoparticulaires
WO2012053768A3 (fr) Composé à base d'aryloxyphénoxyacétyl présentant une activité inhibitrice du hif-1, son procédé de préparation, et composition pharmaceutique le contenant en tant que principe actif
WO2011056785A3 (fr) Compositions de cellulose microcristalline et de phosphate de calcium utiles en tant qu'excipients pharmaceutiques
WO2011073222A3 (fr) Polyesters hyperramifiés à noyau hydrophobe pour la solubilisation d'agents actifs peu solubles
WO2009084041A3 (fr) Compositions pharmaceutiques de dexibuprofène
WO2012019428A8 (fr) Dérivés de benzohydrol, procédé de préparation et utilisation pharmaceutique de ceux-ci
WO2009084036A3 (fr) Composition utilisée pour traiter les infections virales
WO2010013835A3 (fr) Composition pharmaceutique solide
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir
WO2008084823A1 (fr) Composition de dépôt brun et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10807512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10807512

Country of ref document: EP

Kind code of ref document: A2